• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Shortening the treatment of tuberculosis.

作者信息

Mitchison Denis A

出版信息

Nat Biotechnol. 2005 Feb;23(2):187-8. doi: 10.1038/nbt0205-187.

DOI:10.1038/nbt0205-187
PMID:15696148
Abstract
摘要

相似文献

1
Shortening the treatment of tuberculosis.缩短结核病的治疗疗程。
Nat Biotechnol. 2005 Feb;23(2):187-8. doi: 10.1038/nbt0205-187.
2
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.一种对结核分枝杆菌的ATP合酶有活性的二芳基喹啉类药物。
Science. 2005 Jan 14;307(5707):223-7. doi: 10.1126/science.1106753. Epub 2004 Dec 9.
3
Microbiology. TB--a new target, a new drug.微生物学。结核病——一个新靶点，一种新药。
Science. 2005 Jan 14;307(5707):214-5. doi: 10.1126/science.1108379.
4
Medicine. New TB drug promises shorter, simpler treatment.医学。新型结核病药物有望实现更短、更简便的治疗。
Science. 2004 Dec 10;306(5703):1872. doi: 10.1126/science.306.5703.1872.
5
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.新型、强效、口服生物可利用且具有选择性的分枝杆菌ATP合酶抑制剂，对复制期和非复制期结核分枝杆菌均显示出活性。
Bioorg Med Chem. 2015 Feb 15;23(4):742-52. doi: 10.1016/j.bmc.2014.12.060. Epub 2015 Jan 2.
6
Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.抗结核化合物库筛选鉴定出新型结核分枝杆菌ATP合酶抑制剂。
Tuberculosis (Edinb). 2018 Jan;108:56-63. doi: 10.1016/j.tube.2017.10.008. Epub 2017 Oct 25.
7
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.通过使用体外药效学感染模型和数学模型来选择抑制结核分枝杆菌耐药性的莫西沙星剂量。
J Infect Dis. 2004 Nov 1;190(9):1642-51. doi: 10.1086/424849. Epub 2004 Sep 24.
8
5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.5-硝基-2,6-二氧代六氢-4-嘧啶甲酰胺：合成、体外抗分枝杆菌活性、细胞毒性和异柠檬酸裂解酶抑制研究。
J Enzyme Inhib Med Chem. 2010 Dec;25(6):765-72. doi: 10.3109/14756360903425221. Epub 2010 Jun 23.
9
The diarylquinoline TMC207 for multidrug-resistant tuberculosis.用于耐多药结核病的二芳基喹啉类药物TMC207
N Engl J Med. 2009 Jun 4;360(23):2397-405. doi: 10.1056/NEJMoa0808427.
10
Infectious disease. Approval of novel TB drug celebrated--with restraint.传染病。新型结核病药物获批，庆祝但有所克制。
Science. 2013 Jan 11;339(6116):130. doi: 10.1126/science.339.6116.130.

引用本文的文献

1
Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin.利托那韦增效的阿扎那韦每日 2 次给药与利福平联合应用的药代动力学和安全性。
Clin Infect Dis. 2024 May 15;78(5):1246-1255. doi: 10.1093/cid/ciad700.
2
Overcoming Drug Resistance: Novel Medications and Repositioning Strategies.克服耐药性：新型药物与重新定位策略
ACS Omega. 2023 Sep 1;8(36):32244-32257. doi: 10.1021/acsomega.3c02563. eCollection 2023 Sep 12.
3
and Activity of Oxazolidinone Candidate OTB-658 against Mycobacterium tuberculosis.并且 恶唑烷酮候选药物 OTB-658 对结核分枝杆菌的活性。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0097421. doi: 10.1128/AAC.00974-21. Epub 2021 Aug 16.
4
Deletion of Abates Reactivation of Latent Mycobacterium tuberculosis in Mice.缺失可阻止潜伏结核分枝杆菌在小鼠体内的激活。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02095-20.
5
Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.莫西沙星替代方案在康奈尔小鼠模型中对持续存在的结核分枝杆菌无效。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00190-18. Print 2018 Jul.
6
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.在改良的康奈尔小鼠模型中使用一线药物组合对结核分枝杆菌的清除率、持续亚群清除及复发率的研究
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4778-85. doi: 10.1128/AAC.02548-15. Print 2016 Aug.
7
High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo.高剂量利福平可杀死持留菌，缩短治疗时间，并降低体内外的复发率。
Front Microbiol. 2015 Jun 23;6:641. doi: 10.3389/fmicb.2015.00641. eCollection 2015.
8
Identification of plant-derived natural products as potential inhibitors of the Mycobacterium tuberculosis proteasome.鉴定植物源天然产物作为潜在的结核分枝杆菌蛋白酶体抑制剂。
BMC Complement Altern Med. 2014 Oct 15;14:400. doi: 10.1186/1472-6882-14-400.
9
Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis.肺结核治疗期间痰液监测对预测结局的作用：系统评价和荟萃分析。
Lancet Infect Dis. 2010 Jun;10(6):387-94. doi: 10.1016/S1473-3099(10)70071-2.
10
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.抗结核新药：临床研发中的问题、进展及药物评估
Antimicrob Agents Chemother. 2009 Mar;53(3):849-62. doi: 10.1128/AAC.00749-08. Epub 2008 Dec 15.